FI88037B - Foerfarande foer framstaellning av farmaceutiskt vaerdefullt kristallint (4r,5s,6s,8r,2's,4's)-3-/4-(2-dimetylaminokarbonyl)-pyrrolidinyltio/-4-metyl-6-(1-hydroxietyl)-1-azabicyklo-/3,2,0/-hept-2-en-7-on-2-karboxylsyratrihydrat - Google Patents

Foerfarande foer framstaellning av farmaceutiskt vaerdefullt kristallint (4r,5s,6s,8r,2's,4's)-3-/4-(2-dimetylaminokarbonyl)-pyrrolidinyltio/-4-metyl-6-(1-hydroxietyl)-1-azabicyklo-/3,2,0/-hept-2-en-7-on-2-karboxylsyratrihydrat

Info

Publication number
FI88037B
FI88037B FI873299A FI873299A FI88037B FI 88037 B FI88037 B FI 88037B FI 873299 A FI873299 A FI 873299A FI 873299 A FI873299 A FI 873299A FI 88037 B FI88037 B FI 88037B
Authority
FI
Finland
Prior art keywords
vaerdefullt
karboxylsyratrihydrat
framstation
pyrrolidinylthio
dimethylaminocarbonyl
Prior art date
Application number
FI873299A
Other languages
English (en)
Other versions
FI873299A (fi
FI873299A0 (fi
FI88037C (fi
Inventor
Makoto Sunagawa
Yutaka Isobe
Yutaka Takeuchi
Haruki Matsumura
Tetsuo Noguchi
Yukio Ozaki
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Publication of FI873299A0 publication Critical patent/FI873299A0/fi
Publication of FI873299A publication Critical patent/FI873299A/fi
Publication of FI88037B publication Critical patent/FI88037B/fi
Application granted granted Critical
Publication of FI88037C publication Critical patent/FI88037C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI873299A 1986-07-30 1987-07-29 Foerfarande foer framstaellning av farmaceutiskt vaerdefullt kristallint (4r,5s,6s,8r,2's,4's)-3-/4-(2-dimetylaminokarbonyl)-pyrrolidinyltio/-4-metyl-6-(1-hydroxietyl)-1-azabicyklo-/3,2,0/-hept-2-en-7-on-2-karboxylsyratrihydrat FI88037C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP17932186 1986-07-30
JP17932186 1986-07-30
JP15776987 1987-06-26
JP15776987 1987-06-26

Publications (4)

Publication Number Publication Date
FI873299A0 FI873299A0 (fi) 1987-07-29
FI873299A FI873299A (fi) 1988-01-31
FI88037B true FI88037B (fi) 1992-12-15
FI88037C FI88037C (fi) 1993-03-25

Family

ID=26485103

Family Applications (1)

Application Number Title Priority Date Filing Date
FI873299A FI88037C (fi) 1986-07-30 1987-07-29 Foerfarande foer framstaellning av farmaceutiskt vaerdefullt kristallint (4r,5s,6s,8r,2's,4's)-3-/4-(2-dimetylaminokarbonyl)-pyrrolidinyltio/-4-metyl-6-(1-hydroxietyl)-1-azabicyklo-/3,2,0/-hept-2-en-7-on-2-karboxylsyratrihydrat

Country Status (20)

Country Link
US (1) US4888344A (fi)
EP (1) EP0256377B1 (fi)
JP (1) JP2665767B2 (fi)
AR (1) AR243189A1 (fi)
AU (1) AU596857B2 (fi)
CA (1) CA1322371C (fi)
DE (1) DE3781980T2 (fi)
DK (1) DK172666B1 (fi)
ES (1) ES2052524T3 (fi)
FI (1) FI88037C (fi)
GR (1) GR3006254T3 (fi)
HK (1) HK169595A (fi)
HU (1) HU199473B (fi)
IE (1) IE60588B1 (fi)
IL (1) IL83372A (fi)
LU (1) LU88635I2 (fi)
MX (1) MX173359B (fi)
NO (2) NO165543C (fi)
NZ (1) NZ221224A (fi)
PH (1) PH24710A (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
KR880006244A (ko) * 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
DE69019610D1 (de) * 1989-07-06 1995-06-29 Banyu Pharma Co Ltd Cyclische Derivate des Amidinylthiocarbapenems.
US5112818A (en) * 1989-12-29 1992-05-12 Banyu Pharmaceutical Co., Ltd. 2-(2-cyclopropylpyrrolidin-4-ylthio)carbapenhem derivatives
TW264475B (fi) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2696807B2 (ja) * 1992-08-06 1998-01-14 田辺製薬株式会社 カルバペネム誘導体の製法
GB9503717D0 (en) * 1995-02-24 1995-04-12 Smithkline Beecham Plc Novel compounds
FR2735474B1 (fr) * 1995-06-13 1997-08-08 Roussel Uclaf Chlorhydrate de zilpaterol sous une forme cristallisee particuliere, son procede de preparation et les produits intermediaires mis en oeuvre
ATE239728T1 (de) * 1997-02-07 2003-05-15 Kyoto Pharma Ind Carbapenemverbindungen, ihre verwendung und zwischenstufen zu ihrer herstellung
PL343728A1 (en) 1998-05-01 2001-09-10 Kyoto Pharmaceutical Ind Carbapenem derivatives, utilization thereof and intermediate compounds of the same
JP4130078B2 (ja) 1999-06-03 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 カルバペネム誘導体結晶と注射製剤
US7041660B2 (en) 1999-07-06 2006-05-09 Sankyo Company, Limited Crystalline 1-methylcarbapenem derivatives
TWI250160B (en) 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound
EP1762236B1 (en) * 2000-05-12 2015-07-15 Septodont Holding SAS Formulations of alpha adrenergic receptor antagonists and their uses
JP5079190B2 (ja) * 2001-04-27 2012-11-21 大日本住友製薬株式会社 アゼチジノン誘導体およびその製造方法
CA2448670A1 (en) * 2001-05-21 2002-11-28 Kyoto Pharmaceutical Industries, Ltd. Carbapenem compound
KR100451672B1 (ko) * 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
EP1426376A4 (en) * 2001-08-13 2004-12-22 Eisai Co Ltd PROCESS FOR THE PREPARATION OF CARBAPENEM-BASED ANTIBIOTICS
WO2003027067A2 (en) * 2001-09-26 2003-04-03 Merck & Co., Inc. Process for making carbapenem compounds
EP1442038A4 (en) * 2001-09-26 2005-01-05 Merck & Co Inc CRYSTALLINE FORMS OF CARBAPENEM ANTIBIOTICS AND MANUFACTURING METHOD
ITMI20012364A1 (it) * 2001-11-09 2003-05-09 Antibioticos Spa Processo di sintesi della cefixima via alchil-o arilsolfonati
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7229630B2 (en) * 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20030236306A1 (en) * 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2004024185A1 (ja) 2002-09-11 2004-03-25 Michio Ishibashi 医薬または化粧料
EP1776365B1 (en) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem intermediate in crystalline form
WO2006035300A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited A process for the preparation of meropenem
JP4547245B2 (ja) * 2004-12-16 2010-09-22 株式会社パーマケム・アジア ペリンドプリルエルブミンのｉ型結晶、及びその製造方法
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20070197781A1 (en) * 2005-07-29 2007-08-23 Neera Tewari Processes for the preparation of carbapenems
WO2007029084A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited A process for the preparation of carbapenem compounds
NZ566460A (en) 2005-09-15 2010-04-30 Orchid Chemicals & Pharm Ltd An improved process for the preparation of beta-lactam antibiotic
CN100497338C (zh) * 2006-01-05 2009-06-10 上海医药工业研究院 4－甲基－7－氧－1－氮杂双环[3.2.0]庚－2－烯－2－羧酸类衍生物的制备方法
KR100781821B1 (ko) * 2006-02-16 2007-12-03 문순구 카르바페넴계 화합물의 제조방법
TW200801004A (en) * 2006-03-28 2008-01-01 Kaneka Corp Improved process for producing carbapenem compound
WO2007125788A1 (ja) * 2006-04-28 2007-11-08 Kaneka Corporation カルバペネム抗生物質中間体の改良された晶析方法
US20100256107A1 (en) * 2007-12-12 2010-10-07 Dainippon Sumitomo Pharma Co., Ltd. Preparation composition
US20090216010A1 (en) * 2008-02-22 2009-08-27 Wei-Hong Tseng Crystalline carbapenem compound and produced method thereof
EP2098525A1 (en) 2008-02-26 2009-09-09 Savior Lifetec Corporation Crystalline carbapenem compound and produced method thereof
SI3494960T1 (sl) * 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
EP2326648B1 (en) * 2008-07-30 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
ES2477290T3 (es) 2009-03-13 2014-07-16 Daewoong Pharmaceutical Co., Ltd. Método mejorado para preparar meropenem usando polvo de zinc
WO2011048583A1 (en) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
WO2011141847A1 (en) * 2010-05-10 2011-11-17 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of meropenem
US9000150B2 (en) 2010-10-22 2015-04-07 Ranbaxy Laboratories Limited Process for the preparation of pure meropenem trihydrate
CN101962383A (zh) * 2010-11-12 2011-02-02 上海巴迪生物医药科技有限公司 一种美罗培南的合成方法
WO2012081033A2 (en) * 2010-12-06 2012-06-21 Sequent Scientific Limited A process for preparation of imipenem
CN102532140B (zh) * 2010-12-21 2015-03-11 北大方正集团有限公司 一种美罗培南三水合物的制备方法
CN102250096B (zh) * 2011-09-05 2016-04-06 江西华邦药业有限公司 一种美罗培南的制备方法
CN103570718B (zh) * 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN103570720B (zh) * 2012-07-31 2016-02-10 新乡海滨药业有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN103570719B (zh) * 2012-07-31 2016-03-02 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
KR101331762B1 (ko) * 2012-12-28 2013-11-20 주식회사 대웅제약 메로페넴의 삼수화물의 제조방법
CN103044429B (zh) * 2013-01-28 2015-04-01 苏州二叶制药有限公司 一种美罗培南的制备方法
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US9795560B2 (en) 2013-02-01 2017-10-24 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
KR102144777B1 (ko) 2013-06-19 2020-08-18 제이더블유중외제약 주식회사 결정형 메로페넴 삼수화물의 제조방법
KR102360512B1 (ko) 2014-03-27 2022-02-10 존슨 맛쎄이 퍼블릭 리미티드 컴파니 카바페넴 항생물질의 제조 방법
CN113164452A (zh) 2018-10-26 2021-07-23 奥库菲尔制药股份有限公司 治疗老花眼、散瞳和其他眼部疾病的方法和组合物
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153486C (da) * 1978-07-03 1988-11-28 Merck & Co Inc Analogifremgangsmaade til fremstilling af krystallinsk n-formimidoyl-thienamycin-monohydrat
EP0113101A1 (en) * 1982-12-30 1984-07-11 Merck & Co. Inc. 6-(1-Hydroxyethyl)-2-SR8-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60104088A (ja) * 1983-11-11 1985-06-08 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
US4748238A (en) * 1984-03-14 1988-05-31 Merck & Co., Inc. Crystalline 1R,5S,6S,8R-1-methyl-2-(N,N-dimethylcarbamimidoylmethylthio)-6-(1-hydroxyethyl)-1-carbapen-2-em-3-carboxylic acid
US4713451A (en) * 1984-04-09 1987-12-15 Merck & Co., Inc. Crystalline dimethyliminothienamycin
US4761408A (en) * 1984-11-02 1988-08-02 Ciba-Geigy Corporation Crystalline aminomethyl compound
NZ214691A (en) * 1984-12-27 1988-08-30 Sumitomo Pharma The preparation of carbapenem derivatives and beta-lactam intermediates
US4788282A (en) * 1985-06-07 1988-11-29 Bristol-Myers Company Deprotection of allylic esters and ethers

Also Published As

Publication number Publication date
IE871959L (en) 1988-01-30
FI873299A (fi) 1988-01-31
IL83372A (en) 1992-05-25
DK172666B1 (da) 1999-05-10
FI873299A0 (fi) 1987-07-29
HK169595A (en) 1995-11-10
HUT44553A (en) 1988-03-28
JPS6434986A (en) 1989-02-06
NO165543C (no) 1991-02-27
MX173359B (es) 1994-02-23
EP0256377A1 (en) 1988-02-24
DK399087D0 (da) 1987-07-30
EP0256377B1 (en) 1992-09-30
NO873205L (no) 1988-02-01
NO165543B (no) 1990-11-19
AU7619687A (en) 1988-03-03
LU88635I2 (fr) 1995-12-01
CA1322371C (en) 1993-09-21
DE3781980T2 (de) 1993-02-18
PH24710A (en) 1990-10-01
IL83372A0 (en) 1987-12-31
NO873205D0 (no) 1987-07-30
ES2052524T3 (es) 1994-07-16
JP2665767B2 (ja) 1997-10-22
NZ221224A (en) 1989-10-27
DE3781980D1 (de) 1992-11-05
HU199473B (en) 1990-02-28
NO1997013I1 (no) 1997-10-17
US4888344A (en) 1989-12-19
IE60588B1 (en) 1994-07-27
GR3006254T3 (fi) 1993-06-21
FI88037C (fi) 1993-03-25
AU596857B2 (en) 1990-05-17
AR243189A1 (es) 1993-07-30
MX7534A (es) 1993-10-01
DK399087A (da) 1988-01-31

Similar Documents

Publication Publication Date Title
FI88037B (fi) Foerfarande foer framstaellning av farmaceutiskt vaerdefullt kristallint (4r,5s,6s,8r,2's,4's)-3-/4-(2-dimetylaminokarbonyl)-pyrrolidinyltio/-4-metyl-6-(1-hydroxietyl)-1-azabicyklo-/3,2,0/-hept-2-en-7-on-2-karboxylsyratrihydrat
NO179639C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte piperidinforbindelser
NO177387C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazo-kondenserte, 6-leddede, heterocykliske forbindelser
AU590403B2 (en) Pharmaceutical composition for the treatment of periodontal diseases
NO174239C (no) Fremgangsmåte for fremstilling av et oralt, farmasöytisk preparat
NO871408D0 (no) Forbedringer ved farmasoeytiske akseptable salter.
IT1235532B (it) Composti carbossiammidici, procedimenti per la preparazione dei medesimi e composizione farmaceutica contenente i medesimi
DK53285D0 (da) (-)-trans-4(4-fluorphenyl)-3-(4-methoxyphenoxy)-methylpiperidin, farmaceutisk acceptable syreadditionssalte heraf og farmaceutisk praeparat indeholdende samme
NO170330C (no) Fremgangsmaate for fremstilling av vesentlig optisk rent monohydrat av s-(-)-propyl-2',6'-pipekoloksylididhydroklorid
NO171909C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydropyridinderivater
DK144685A (da) Substituerede benzopyraner, fremgangsmaader til fremstilling deraf samt deres anvendelse i laegemidler
FI871087A0 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
PT84923A (en) Process for the preparation of 1-(hydroxystyrul)-5h-2,3-benzodiapezine derivatives and pharmaceutical compositions containing the same
IL83194A0 (en) Beta-lactam compound,method for preparing the same,medicinal composition containing the same for infectious bacterial disease therapy and intermediates for synthesis of the same
AU7080587A (en) Therapeutic compositions for veterinary use
DE3361609D1 (en) New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
PT91612A (pt) Process for the preparation pf 2-aza-4(alkoxycarbonyl> spiro<4,5> decan-3-on and of his own acid derivative 1-(aminomethyl)-cyclo-hexane-acetic
NO881884L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater.
NO862390D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydropyridinderivater.
EP0256507A3 (en) 3-(1h-tetrazol-5-yl)oxanilic acid and salts thereof, method for preparing the same and pharmaceutical compositions containing the compound
AR243159A1 (es) Procedimiento de preparacion de acido 1-(3-mercapto-(2s)-metilpropionil)-pirrolidin-(2s)-carboxilico o sus sales farmaceuticamente aceptables.
NO171499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6-dihydro-4h-cyklo-penta(b)tiofen-6-karboksylsyre-derivater
FI89595B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 2-(tioalkylamino)etyl-1H-imidazolderivat
AU3620089A (en) New process for the preparation of n-(23-vinblastinoyl) derivatives of 1-amino-methyl-phosphonic acid
FI894813A (fi) Menetelmä terapeuttisesti aktiivisten 2-metoksikarbonyylisubstituoitujen N,N'-di(trimetoksibentsoyyli)piperatsiinijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L57

Extension date: 20090817

FG Patent granted

Owner name: SUMITOMO PHARMACEUTICALS COMPANY

PC Transfer of assignment of patent

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD.

Free format text: DAINIPPON SUMITOMO PHARMA CO., LTD.

MA Patent expired